ArticleFrontiers in immunology2023
Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Rewriting Inflammation in IBD: Lipidomics from Pathogenesis to Clinical Application.Microorganisms · 2026Review
- A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?Current opinion in lipidology · 2026Review
- Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study.BMC cardiovascular disorders · 2026Article
- Metabolic Disorders and Inflammatory Bowel Diseases: Unraveling Shared Pathways and Clinical Interactions.Metabolites · 2026Review
- Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue.Frontiers in endocrinology · 2026Review
- The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn's disease.Frontiers in immunology · 2026Review
- Systemic PCSK9 elevation characterises autoimmune liver disease across sexes.Scientific reports · 2025Article
- Serum uric acid to high‑density lipoprotein cholesterol ratio as a novel predictor of diabetic nephropathy: a cross‑sectional analysis of NHANES 2011-2018.Clinical and experimental medicine · 2025Article
- Patterns and Correlates of Sedentary Behavior and Physical Activity in Individuals With Crohn's Disease: A Cross-Sectional Study.Crohn's & colitis 360 · 2025Article
- Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Low-Density Lipoprotein Cholesterol as a Protective Factor in COPD and Implications for Statin Therapy: A Multi-Omics Genetic Epidemiology Study.International journal of chronic obstructive pulmonary disease · 2025Article
- Association between serum total cholesterol levels and Crohn's clinical disease severity: a retrospective cross-sectional study.Frontiers in medicine · 2025Article
- Causal effects of circulating lipids and lipid-lowering drugs on the risk of atopic dermatitis: a mendelian randomization study.Archives of dermatological research · 2024Article
- Association of the atherogenic index of plasma and modified triglyceride-glucose indices with digestive diseases among middle-aged and older population in China.Lipids in health and disease · 2024Article
- The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies.Metabolites · 2024Review
- Life's essential 8, genetic susceptibility, and risk of inflammatory bowel diseases: a population-based cohort study.The international journal of behavioral nutrition and physical activity · 2024Article
- Mendelian randomisation analysis for intestinal disease: achievement and future.eGastroenterology · 2024Review
- To explore the causal association between the serum lipid profile and inflammatory bowel disease using bidirectional Mendelian randomisation analysis.eGastroenterology · 2024Article
- Inflammatory cytokines mediating the effect of oral lichen planus on oral cavity cancer risk: a univariable and multivariable mendelian randomization study.BMC oral health · 2024Article
- FOXO3: at the crossroads of metabolic, inflammatory, and tumorigenic remodeling in the colon.American journal of physiology. Gastrointestinal and liver physiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To assess the causal role of lipid traits and lipid-lowering agents in inflammatory bowel disease (IBD). Methods: Univariable mendelian randomization (MR) and multivariable MR (MVMR) analyses were conducted to evaluate the causal association between low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and IBD. Drug-targeted MR analyzed the effects of lipid-lowering drugs on IBD, and network MR was used to analyze potential mediation effects. Results: The levels of HDL-C had an inverse relationship with the risk of Crohn's disease (CD, OR: 0.85, 95% CI: 0.73-0.98, Conclusion: Our study suggested a causal association between HDL-C and IBD, UC and CD. Genetically proxied inhibition of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.